ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Carrick launches to conquer cancer

by Lisa M. Jarvis
October 10, 2016 | APPEARED IN VOLUME 94, ISSUE 40

Backed by $95 million in funding, Carrick Therapeutics has launched with the lofty goal of becoming the leading oncology company in Europe. The biotech start-up has yet to provide substantive details on its scientific strategy but says it will build a portfolio of first-in-class treatments that target the most aggressive and resistant forms of cancer. Carrick has R&D teams in Oxford, Eng­land, and Dublin that are working on three therapeutic programs. It intends to expand its pipeline through academic and pharma ­partnerships.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment